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Another modality to treat esophageal cancer? 
 
Minimally invasive endoscopic therapy has come of age in the last decade. We now treat 
dysplastic Barrett’s esophagus very effectively with endoscopic resection and 
radiofrequency ablation. Endoscopic submucosal dissection is increasingly used for early 
squamous cancers and also for spreading dysplasia within the esophagus. For locally 
advanced disease in both squamous and adenocarcinomas, chemoradiotherapy followed by 
surgery has, in the last few years, become a standard therapy [1]. But how do we help 
people who do not fit the criteria for surgery or who develop recurrent disease, for whom 
very few treatment options remain? In this edition of GIE, Yano et al continue their work in 
this area. They report here on their experience of photodynamic therapy (PDT) as a salvage 
therapy for patients who have previously undergone chemoradiotherapy for squamous cell 
cancer of the esophagus  (REF GIE 2016).   
 
PDT involves the administration of a photosensitizing agent, usually by intravenous 
injection. The agent is then activated by light applied to the selected area. A low-power 
laser is used to avoid heating the tissue. The agent absorbs the energy from the light, and 
this results in the formation of highly active singlet oxygen. This interacts with tissue leading 
to apoptosis and necrosis through a photochemical effect. This approach leads to a highly 
targeted therapy which can be delivered as day case treatment and offers the possibility of 
repeat treatments.  There are, however, significant limitations. Firstly, the drugs produce 
skin photosensitivity which, for older drugs, like the porfimer sodium used in this study, can 
last for months. Tumor selectivity is achieved by shining the light in the correct place, but 
where normal tissue is illuminated, non-specific destruction occurs, and although it is 
claimed that there is no scarring, the reality is that it often does occur.  The promise of a 
gentle, repeatable therapy has not been borne out so far in practice due to the complex 
parameters that need to be optimized.  Laboratory research continues to develop in both 
scope and extent, but very few clinical trials have yet been undertaken successfully. 
 
There are no randomized controlled trials (RCTs) of PDT for esophageal cancer and very few 
in any other cancer type. In fact, the most important RCT was the one which showed the 
value of PDT using the first generation drug, porfimer sodium (Photofrin), to eradicate high 
grade dysplasia in Barrett’s esophagus (BE), which was published in GIE [2]. Our group later 
compared porfimer sodium with the shorter acting 5-aminolevulinic acid (ALA) and although 
neither drug was particularly successful in our study, ALA did have fewer side effects [3]. 
PDT is no longer used but this work paved the way for the development of radiofrequency 
ablation of BE which has been very successful [4,5], although its utility in squamous 
dysplasia has not yet been proven.  
 
Not only are there are no RCTs of PDT for esophageal cancer, but there no large prospective 
cohort studies either. Retrospective cohorts simply give us an indication of areas where 
better quality studies should be undertaken.  The trial published in this edition of the 
journal is a retrospective analysis of patients who underwent salvage PDT after failed 
primary treatment with chemoradiotherapy. The work offers some hope, although rather 
limited in scope. The treatment led to response in 58% and long term survival in 35%, 
particularly in those who had T1 or T2 recurrence only. If recurrence was more advanced, 
the treatment did not work.  
 
These findings support and extend previously published retrospective work by others. In 
one case series 5-year disease-specific survival was 72% in 56 patients treated with PDT as 
monotherapy, and in another of 21 patients, mean local progression-free survival was 60 
months. In a case series of 38 patients, nine of whom received repeat PDT sessions, mean 
disease-free survival was 32 months and in another, 54% (13/24) of patients were alive 
without recurrence at a mean follow-up of 21 months [6]. So it does appear that PDT 
treatment may hold some promise for appropriately selected patients.  
 
Safety Concerns 
 
Apart from PDT induced skin photosensitivity, there is the well known risk of esophageal 
strictures. Some of these can be very difficult to treat, requiring repeated endoscopic 
dilatations. But what happens when a T3 or T4 tumor which is invading through the entire 
thickness of the esophageal wall is treated? Radiotherapy, which requires repeated dosing 
over some weeks leads to stricturing. There is plenty of evidence that PDT does not affect 
the collagen scaffold that is important in maintaining the integrity of hollow organs. But in 
full thickness tumors, the scaffold has been destroyed. Single dose PDT will result in rapid 
destruction of tumor and may lead to esophageal perforation as there is no time for the 
supporting scaffold to regenerate. This was seen in the 5/113 patients in the Yano study and 
has been reported by others also at rates of up to 8% [6].  This is not a good selling point for 
a treatment!  
 
Is there a future for PDT? 
 
There are good quality data for use of PDT in a variety of premalignant diseases such as 
actinic keratosis in the skin as well as basal cell carcinoma and recently, it has been 
proposed for non-cancer applications including infection and to accelerate regeneration of 
injured tissues. We have explored its use for C. difficile diarrhea in the laboratory [7]. Phase 
2 and 3 RCTs are now underway for cancers of the prostate and lung. But the modality has 
not been subjected to high quality trials in other promising areas such as treatment of 
premalignant lesions of the mouth or for palliation of cholangiocarcinoma, where some very 
compelling early data have been presented [8].  
 
Prolonged skin photosensitivity is a concern for clinicians and patients alike. Newer drugs 
may have significant advantages over the ones used previously. Drugs with a shorter 
biological half-life would reduce the duration of skin photosensitivity and might also open 
the way to repeat treatments.  Slower, more controlled, tissue destruction could permit 
preferential regeneration of normal tissues, thus lowering the risk of perforation, and, if the 
PDT drug is preferentially taken up in the mucosa, as ALA is, there may be fewer side effects 
[3]. But there are other benefits to be had. For example, porfimer sodium, is activated at 
630nm, in the red part of the visible spectrum. The depth of penetration of light at this 
wavelength is no more than 1cm. Penetration depth rises with longer wavelengths.   It is 
quite conceivable that some of the newer drugs which are illuminated in the far red end of 
the visible spectrum, or even in the near infra-red, might be used to successfully target not 
only the primary tumor in the esophageal wall but also local para-esophageal lymph node 
metastases.  This would raise the question as to whether this treatment approach could be 
used instead of esophagectomy.  
 
An even more elegant application would be better targeting using anitbody fragments or 
other small molecule targeting agents such as nanoparticles. These would not only increase 
selectivity for cancer cells, but could completely remove the problem of skin 
photosensitivity as these drugs would be cleared from the bloodstream within minutes. 
Proof of principle for this approach already exists [9] 
 
 So although we have not yet proven the value of this technology in the clinical 
environment, there is reason to continue research in this field. Photodynamic therapy may 
yet replace esophagectomy as the primary treatment for locally invasive esophageal cancer. 
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